The price for treatment of chronic skin diseases: Different approaches

Dermatology

Volumn 214, Issue 1, 2006, Pages 6-7

  Fluhr, Joachim W ^a   Jünger, Michael ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; IMMUNOMODULATING AGENT;

ATOPIC DERMATITIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; EDITORIAL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL DISCHARGE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MEDICAL SERVICE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SKIN DISEASE; ULTRAVIOLET IRRADIATION;

CHRONIC DISEASE; HEALTH CARE COSTS; HUMANS; SKIN DISEASES;

EID: 33845937615     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096905     Document Type: Editorial

References (12)

1. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Stevens SR, Whitaker-Worth DL, Cheng JW, Tong KB: Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002;46:361-370.
2. Berger K, Ehlken B, Kugland B, Augustin M: Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005;3:511-518.
3. Schmitt J, Heese E, Wozel G, Meurer M: Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study. Dermatology 2007;214:68-76.
4. Stern RS: The benefits, costs and risks of topical tar preparations in the treatment of psoriasis: considerations of cost effectiveness. Ann Acad Med Singapore 1988;17:473-476.
5. Stern RS: Long-term use of psoralens and ultraviolet A for psoriasis: evidence for efficacy and cost savings. J Am Acad Dermatol 1986;14:520-526.
6. Stern RS, Thibodeau LA, Kleinerman RA, Parrish JA, Fitzpatrick TB, Bleich HL: Effect of methoxsalen photochemotherapy on cost of treatment for psoriasis: an example of technological assessment. JAMA 1981;245:1913-1918.
7. Nijsten T, Unaeze J, Stern RS: Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs Rasch analysis. Br J Dermatol 2006;154:692-700.
8. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004;9:136-139.
9. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M: Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212:137-144.
10. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W: Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003;148:1153-1160.
11. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D: Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-year retrospective study. Eur Respir J 2003;21:116-122.
12. Schmitt JM, Ford DE: Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:102-110.